Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211685 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
A Phase 2 study, sponsored by Bayer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07211685 is a Phase 2 study that is actively recruiting participants, run by Bayer. The registered enrollment target is 60 participants.
The verdict
NCT07211685, a Phase 2 study, is actively recruiting participants, sponsored by Bayer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time. The kidneys soon lose their ability to remove waste products from the body properly, resulting in end-stage kidney disease. A common sign of decreasing kidney function is the presence of excess protein in the urine that is not usually found with healthy kidneys. This condition is known as proteinuria. The study drug, BAY 3401016 (a monoclonal antibody), is a type of medicine that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in causing kidney damage in AS. By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS. The main purpose of this study is to learn more about how well BAY 3401016 works in slowing down the loss in kidney function in adults with a rapidly progressing AS.
Interventions
- OTHER Placebo
- BIOLOGICAL BAY 3401016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2028-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07211685
The ClinicalTrials.gov registry entry for NCT07211685 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07211685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07211685 about?
NCT07211685 is a clinical study titled "A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome". Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing...
What is the current status of trial NCT07211685?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-11-19. Estimated completion is 2028-07-27.
What interventions are being tested in trial NCT07211685?
The interventions under investigation include: Placebo (OTHER), BAY 3401016 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07211685?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.